392 related articles for article (PubMed ID: 24588504)
21. Regional but not global brain damage contributes to fatigue in multiple sclerosis.
Rocca MA; Parisi L; Pagani E; Copetti M; Rodegher M; Colombo B; Comi G; Falini A; Filippi M
Radiology; 2014 Nov; 273(2):511-20. PubMed ID: 24927473
[TBL] [Abstract][Full Text] [Related]
22. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis.
Schmierer K; Parkes HG; So PW; An SF; Brandner S; Ordidge RJ; Yousry TA; Miller DH
Brain; 2010 Mar; 133(Pt 3):858-67. PubMed ID: 20123726
[TBL] [Abstract][Full Text] [Related]
23. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction.
Sanfilipo MP; Benedict RH; Sharma J; Weinstock-Guttman B; Bakshi R
Neuroimage; 2005 Jul; 26(4):1068-77. PubMed ID: 15961046
[TBL] [Abstract][Full Text] [Related]
24. MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.
Filippi M; Rocca MA
J Neurol; 2005 Nov; 252 Suppl 5():v16-24. PubMed ID: 16254697
[TBL] [Abstract][Full Text] [Related]
25. What you cannot get from routine MRI of MS patient and why - The growing need for atrophy assessment and seeing beyond the plaque.
Hartel M; Kluczewska E; Pierzchała K; Adamczyk-Sowa M; Karpe J
Neurol Neurochir Pol; 2016; 50(2):123-30. PubMed ID: 26969569
[TBL] [Abstract][Full Text] [Related]
26. Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability.
Charil A; Dagher A; Lerch JP; Zijdenbos AP; Worsley KJ; Evans AC
Neuroimage; 2007 Jan; 34(2):509-17. PubMed ID: 17112743
[TBL] [Abstract][Full Text] [Related]
27. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
[TBL] [Abstract][Full Text] [Related]
28. Gray matter involvement in patients with multiple sclerosis as shown by magnetic resonance imaging.
Rumzan R; Chen X; Li YM
Chin Med J (Engl); 2012 Jul; 125(13):2361-4. PubMed ID: 22882862
[TBL] [Abstract][Full Text] [Related]
29. Low degree of cortical pathology is associated with benign course of multiple sclerosis.
Calabrese M; Favaretto A; Poretto V; Romualdi C; Rinaldi F; Mattisi I; Morra A; Perini P; Gallo P
Mult Scler; 2013 Jun; 19(7):904-11. PubMed ID: 23069877
[TBL] [Abstract][Full Text] [Related]
30. Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: relation to brain findings and clinical disability.
Daams M; Weiler F; Steenwijk MD; Hahn HK; Geurts JJ; Vrenken H; van Schijndel RA; Balk LJ; Tewarie PK; Tillema JM; Killestein J; Uitdehaag BM; Barkhof F
Mult Scler; 2014 Dec; 20(14):1860-5. PubMed ID: 24812042
[TBL] [Abstract][Full Text] [Related]
31. White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI.
Mühlau M; Buck D; Förschler A; Boucard CC; Arsic M; Schmidt P; Gaser C; Berthele A; Hoshi M; Jochim A; Kronsbein H; Zimmer C; Hemmer B; Ilg R
Mult Scler; 2013 Oct; 19(11):1485-92. PubMed ID: 23462349
[TBL] [Abstract][Full Text] [Related]
32. What explains gray matter atrophy in long-standing multiple sclerosis?
Steenwijk MD; Daams M; Pouwels PJ; Balk LJ; Tewarie PK; Killestein J; Uitdehaag BM; Geurts JJ; Barkhof F; Vrenken H
Radiology; 2014 Sep; 272(3):832-42. PubMed ID: 24761837
[TBL] [Abstract][Full Text] [Related]
33. T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis.
Neema M; Stankiewicz J; Arora A; Dandamudi VS; Batt CE; Guss ZD; Al-Sabbagh A; Bakshi R
J Neuroimaging; 2007 Apr; 17 Suppl 1():16S-21S. PubMed ID: 17425729
[TBL] [Abstract][Full Text] [Related]
34. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis.
Bakshi R; Dandamudi VS; Neema M; De C; Bermel RA
J Neuroimaging; 2005; 15(4 Suppl):30S-45S. PubMed ID: 16385017
[TBL] [Abstract][Full Text] [Related]
35. The histopathology of grey matter demyelination in multiple sclerosis.
Bø L
Acta Neurol Scand Suppl; 2009; (189):51-7. PubMed ID: 19566500
[TBL] [Abstract][Full Text] [Related]
36. Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration.
Vigeveno RM; Wiebenga OT; Wattjes MP; Geurts JJ; Barkhof F
J Magn Reson Imaging; 2012 Jul; 36(1):1-19. PubMed ID: 22696123
[TBL] [Abstract][Full Text] [Related]
37. Exploration of the relationships between regional grey matter atrophy and cognition in multiple sclerosis.
Nocentini U; Bozzali M; Spanò B; Cercignani M; Serra L; Basile B; Mannu R; Caltagirone C; De Luca J
Brain Imaging Behav; 2014 Sep; 8(3):378-86. PubMed ID: 22584774
[TBL] [Abstract][Full Text] [Related]
38. The role of magnetic resonance imaging in the study of multiple sclerosis: diagnosis, prognosis and understanding disease pathophysiology.
Filippi M; Rocca MA
Acta Neurol Belg; 2011 Jun; 111(2):89-98. PubMed ID: 21748926
[TBL] [Abstract][Full Text] [Related]
39. Gray matter pathology in (chronic) MS: modern views on an early observation.
Geurts JJ; Stys PK; Minagar A; Amor S; Zivadinov R
J Neurol Sci; 2009 Jul; 282(1-2):12-20. PubMed ID: 19249061
[TBL] [Abstract][Full Text] [Related]
40. Cortical pathology and cognitive impairment in multiple sclerosis.
Calabrese M; Rinaldi F; Grossi P; Gallo P
Expert Rev Neurother; 2011 Mar; 11(3):425-32. PubMed ID: 21375447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
